関連する実験動画

Updated: Jan 15, 2026

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

慢性B型肝炎患者のガイドラインに基づくモニタリング遵守率の低さ：定量的および定性的研究の混合

Cui-Ling Huang¹, Cheng-Dian Lan¹, Ying Yu²

¹Department of General Practice, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, 361006, China.

Journal of infection in developing countries

|January 13, 2026

要旨

Introduction:

Adherence to guideline-based monitoring (GBM) for chronic hepatitis B (CHB) in China remains understudied. This mixed-methods study assessed GBM adherence and explored patient-reported barriers.

Methodology:

A mixed study was conducted at the Zhongshan Hospital (Xiamen), Fudan University, China. Patients visiting the outpatient department of the hospital between January 2018 and December 2018 were included for the quantitative component. Clinical and biochemical data were retrieved from the hospital's electronic medical record system. Adherence to GBM was defined as regular monitoring of alanine aminotransferase (ALT), hepatitis B virus DNA (HBV-DNA), alpha-fetoprotein (AFP), and liver imaging; at least annually during the 2-year follow-up period. The qualitative component involved semi-structured interviews with thematic and content analysis.

Results:

Among the 402 eligible CHB outpatients, only 103 (25.6%) patients presented good adherence to GBM. Specifically, 171 (42.5%) patients were monitored at least annually for ALT and HBV-DNA, while 107 (26.6%) were monitored for AFP and liver imaging. The factors associated with adherence to GBM included receiving antiviral treatment (OR = 3.54 (1.59-7.86)) and completing initial liver imaging (OR = 4.78 (2.04-9.83)). The reasons for non-adherence included inadequate monitoring tests and health education by healthcare providers, patients' perception of not needing frequent monitoring, forgetfulness, cost concerns, and complex hospital visit procedures.

Conclusions:

Adherence to GBM among CHB patients was suboptimal despite guideline recommendations. Enhanced efforts and interventions, such as combining technology-driven tools, targeted education for providers and patients, and primary care integration are essential.

キーワード:

遵守慢性B型肝炎モニタリング定性的定量的

さらに関連する動画

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

関連する概念動画

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...

Chronic Pancreatitis II: Collaborative Care

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...